To address the lack of guidance for clinicians in their care of children with critical asthma, a multidisciplinary team of medical providers used Grading of Recommendations, Assessment, Development, and Evaluation methodology to make the following recommendations: 1. We suggest the use of continuous inhaled short-acting β agonist (SABA) over frequent intermittent SABA in children treated for critical asthma. (Conditional recommendation, very low certainty of evidence) 2. We suggest the use of either high- or low-dose continuous inhaled SABA regimens in children treated for critical asthma. (Conditional recommendation, very low certainty of evidence) 3. We suggest the use of either dexamethasone or methylprednisolone (or an equivalent dose of prednisone/prednisolone) for children treated for critical asthma. (Conditional recommendation, very low certainty of evidence) 4. We suggest the use of intravenous (IV) magnesium (intermittent or continuous) as an adjunct therapy in children treated for critical asthma. (Conditional recommendation, low certainty of evidence) 5. We cannot recommend for or against the use of IV methylxanthines as an adjunct therapy in children treated for critical asthma. (Conditional recommendation, very low certainty of evidence) 6. We suggest the use of an IV SABA infusion as an adjunct therapy in children treated for critical asthma. (Conditional recommendation, low certainty of evidence) 7. We cannot recommend for or against the application of high-flow nasal cannula versus conventional oxygen therapy in children presenting with critical asthma with persistent hypoxemia and/or respiratory distress. (Conditional recommendation, very low certainty of evidence) 8. We suggest the use of bi-level positive airway pressure over conventional oxygen therapy in children presenting with critical asthma with persistent hypoxemia and/or respiratory distress. (Conditional recommendation, very low certainty of evidence) 9. We cannot recommend for or against the application of bi-level positive airway pressure over high-flow nasal cannula for children hospitalized with critical asthma with persistent hypoxemia and/or respiratory distress. (Conditional recommendation, very low certainty of evidence) 10. We cannot recommend for or against the application of heliox in children treated for critical asthma. (Conditional recommendation, very low certainty of evidence) 11. We suggest the use of a dedicated protocol or pathway for managing children treated for critical asthma. (Conditional recommendation, low certainty of evidence).

为了解决临床医生在护理重症哮喘患儿时缺乏指导的问题，一个由医疗服务提供者组成的多学科团队采用了建议分级、评估、发展和评价的方法，提出了以下建议：1.我们建议在治疗危重哮喘患儿时使用持续吸入短效β受体激动剂（SABA），而不是频繁间歇使用SABA。(有条件推荐，证据确定性极低）2.我们建议对接受危重哮喘治疗的儿童使用高剂量或低剂量持续吸入SABA方案。(有条件推荐，证据确定性极低）3.我们建议对接受危重哮喘治疗的儿童使用地塞米松或甲基强的松龙（或同等剂量的泼尼松/强的松龙）。(有条件推荐，证据确定性极低）4.我们建议对接受危重哮喘治疗的儿童使用静脉注射（IV）镁（间歇或持续）作为辅助治疗。(有条件推荐，证据确定性低）5.我们无法推荐或反对将静脉注射甲基黄嘌呤作为治疗危重哮喘患儿的辅助疗法。(有条件推荐，证据确定性极低）6.我们建议对接受危重哮喘治疗的儿童使用静脉注射SABA作为辅助疗法。(有条件推荐，证据确定性低）7.对于出现持续低氧血症和/或呼吸窘迫的危重哮喘患儿，我们无法推荐使用高流量鼻插管或传统氧疗。(有条件推荐，证据确定性极低）8.我们建议对出现持续低氧血症和/或呼吸困难的危重哮喘患儿使用双水平气道正压疗法，而非传统的氧气疗法。(有条件推荐，证据确定性极低）9.对于因持续低氧血症和/或呼吸窘迫而住院的危重哮喘患儿，我们不建议使用双水平气道正压疗法，也不建议使用高流量鼻插管疗法。(有条件推荐，证据确定性极低）10.我们无法建议是否对接受危重哮喘治疗的儿童使用heliox。(有条件推荐，证据确定性极低）11.我们建议使用专门的方案或路径来管理接受危重哮喘治疗的儿童。(有条件推荐，证据确定性低）。